Canada: Intellectual Property

On June 8, 2012, Genentech’s lawsuit seeking a declaration that US Patent No. 6,733,752 was invalid and not-infringed by Genentech’s trastuzumab product (HERCEPTIN).

Health Canada specifically contemplates certain proteins as SEBs in its Guidance, although Health Canada has not limited SEBs to only particular classes of drugs.

On May 23, 2012, the Federal Court held that Merck Frosst Canada Ltd. ("Merck") is liable to Apotex Inc. ("Apotex") for damages under section 8 of the Patented Medicines (Notice of Compliance) Regulations (the "Regulations"), but exercised its discretion to reduce the amount of compensation payable based on a defence of ex turpi causa.

In today's global economy, businesses, entrepreneurs, and creatives frequently operate across borders.

The U.S. Special 301 Report is an annual review conducted by the Office of the United States Trade Representative (USTR) that evaluates the intellectual property (IP) protection and enforcement practices of U.S. trading partners.

Artificial Intelligence, or AI, has been and continues to be one of the biggest topics of conversation in the music industry since the advent of digital music distribution.

In a major legal win for Canadian agribusiness innovation, Agriculture and Agri-Food Canada (AAFC) has successfully defended its intellectual property rights in the United States over the Staccato cherry, a late-ripening variety developed in Summerland, British Columbia.

In Ontario, business owners typically consider franchising versus licensing as they plan to grow their company. Both methods promote growth through the resources of a third party, but they work in dramatically different ways.

In part one of our IP licensing primer series, we discussed the concept of IP licensing and how the type of IP being licensed, ownership of the IP and other details can impact licensing agreements.

Expanding into Asia offers Canadian businesses enormous potential—but it also exposes them to serious intellectual property (IP) risks.

Semaglutide, the blockbuster GLP-1 receptor agonist marketed under names like Ozempic® (type 2 diabetes) and Wegovy® (weight loss), has rapidly become one of the most consequential drugs in modern healthcare.

In today's global economy, businesses, entrepreneurs, and creatives frequently operate across borders.